Advanced Filters
noise

melanoma Clinical Trials

A listing of melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 463 clinical trials
C Clinical Trials Group

Adjuvant Quisinostat in High-Risk Uveal Melanoma

The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.

19 years of age All Phase 2

In Vivo Liquid Biopsy of Melanoma (Cytophone)

The Cytophone is a first in the world patented system to identify and count single circulating melanoma cells in blood circulation inside the human body. The Cytophone has a unique capability to find rare melanoma cells in the blood by an assessment of 100-500 times greater amounts of blood volume …

18 - 80 years of age All Phase N/A
J Joaquín Calatayud, PhD

Resistance Exercise in Patients With Ocular Melanoma

Choroidal melanoma (CM) is one of the most common intraocular cancers worldwide. During treatment with episcleral brachytherapy, patients require a week of hospitalization in isolation. The primary aim of this study will be to investigate the effects of resistance training during hospitalization on health-related blood biomarkers in CM patients. Our …

18 years of age All Phase N/A

Intratumoral PH-762 for Cutaneous Carcinoma

The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants …

18 years of age All Phase 1
A Antoni Ribas

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study …

18 - 70 years of age All Phase 1
I Inayaa Johnson, B.S.

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

The primary aim of the study is to establish the maximum-tolerated dose (MTD) of 225Ac-MTI-201 in participants with metastatic uveal melanoma. The secondary aims are to describe the pharmacokinetics of 225Ac-MTI-201 and the toxic effects of 225Ac-MTI-201 in participants with metastatic uveal melanoma.

18 years of age All Phase 1
M MERLIN JEAN LOUIS, PharmD,PhD

Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL)

PERCIMEL is an open multicentric study. The purpose of this study is to assess the interest of molecular analysis on circulating tumor DNA in the follow-up of the disease.

18 years of age All Phase N/A
D Daan Rauwerdink, drs

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Phase 2 open-label single arm intervention study administering encorafenib/binimetinib in neo-adjuvant setting followed by surgery and subsequent adjuvant encorafenib/binimetinib in in-transit melanoma patients without lymph node and distant metastases.

18 years of age All Phase 2
R Ryan Sullivan, MD

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

The purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and infliximab in treating metastatic melanoma.

18 years of age All Phase 2
J Jun Guo, Director

OH2 Injection in Combination With HX008 for Melanoma.

This phase Ib study evaluates the safety and efficacy of OH2 in combination with HX008, an anti-PD-1 antibody, in patients with Melanoma. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the …

18 - 75 years of age All Phase 1/2

Simplify language using AI